BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kourie H, Auclin E, Cunha AS, Gaujoux S, Bruzzi M, Sauvanet A, Lourenco N, Trouilloud I, Louafi S, El-Hajjar A, Vaillant JC, Smith D, Touchefeu Y, Bachet JB, Pietrasz D, Taieb J. Characteristic and outcomes of patients with pathologic complete response after preoperative treatment in borderline and locally advanced pancreatic adenocarcinoma: An AGEO multicentric retrospective cohort. Clin Res Hepatol Gastroenterol 2019;43:663-8. [PMID: 31029644 DOI: 10.1016/j.clinre.2019.03.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Barrak D, Villano AM, Villafane-Ferriol N, Stockton LG, Hill MV, Deng M, Handorf EA, Reddy SS. Total neoadjuvant therapy for pancreatic adenocarcinoma increases probability for a complete pathologic response. Eur J Surg Oncol 2022:S0748-7983(21)01445-1. [PMID: 35016837 DOI: 10.1016/j.ejso.2021.12.473] [Reference Citation Analysis]
2 Kim RY, Christians KK, Aldakkak M, Clarke CN, George B, Kamgar M, Khan AH, Kulkarni N, Hall WA, Erickson BA, Evans DB, Tsai S. Total Neoadjuvant Therapy for Operable Pancreatic Cancer. Ann Surg Oncol 2021;28:2246-56. [PMID: 33000372 DOI: 10.1245/s10434-020-09149-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Attard JA, Farrugia A, Pathanki A, Roberts KJ, Dasari B, Isaac J, Ma YT, Chatzizacharias NA. Treatment Strategies for the Optimal Management of Locally Advanced Pancreatic Adenocarcinoma With Curative Intent: A Systematic Review. Pancreas 2020;49:1264-75. [PMID: 33122513 DOI: 10.1097/MPA.0000000000001694] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Soer EC, Verbeke CS. Pathology reporting of margin status in locally advanced pancreatic cancer: challenges and uncertainties. J Gastrointest Oncol 2021;12:2512-20. [PMID: 34790412 DOI: 10.21037/jgo-20-391] [Reference Citation Analysis]
5 Napolitano F, Formisano L, Giardino A, Girelli R, Servetto A, Santaniello A, Foschini F, Marciano R, Mozzillo E, Carratù AC, Cascetta P, De Placido P, De Placido S, Bianco R. Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer (LAPC) Patients with FOLFIRINOX or Gemcitabine NabPaclitaxel: A Single-Center Experience and a Literature Review. Cancers (Basel) 2019;11:E981. [PMID: 31337045 DOI: 10.3390/cancers11070981] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
6 Zhou Y, Liao S, You J. Pathological complete response after neoadjuvant therapy for pancreatic ductal adenocarcinoma does not equal cure. ANZ J Surg 2021;91:E254-9. [PMID: 33634945 DOI: 10.1111/ans.16665] [Reference Citation Analysis]
7 Rangelova E, Bratlie SO. How to select the most appropriate adjuvant treatment after neoadjuvant treatment and resection for locally advanced pancreatic cancer? J Gastrointest Oncol 2021;12:2521-35. [PMID: 34790413 DOI: 10.21037/jgo-21-474] [Reference Citation Analysis]
8 Ma W, Wei M, Han Z, Tang Y, Pan Q, Zhang G, Ren J, Huan Y, Li N. The added value of intravoxel incoherent motion diffusion weighted imaging parameters in differentiating high-grade pancreatic neuroendocrine neoplasms from pancreatic ductal adenocarcinoma. Oncol Lett 2019;18:5448-58. [PMID: 31612053 DOI: 10.3892/ol.2019.10863] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]